1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Global Collaborative R&D Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015

The Global Collaborative R&D Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 report provides comprehensive understanding and unprecedented access to the collaborative R&D partnering deals and agreements entered into by the worlds leading healthcare companies.

The Global Collaborative R&D Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies.

The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual collaborative R&D contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of collaborative R&D dealmaking and business activities.

The initial chapters of this report provide an orientation of collaborative R&D dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in collaborative R&D as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of collaborative R&D deals. The chapter includes numerous case studies to enable understanding of both pure collaborative R&D deals and multicomponent deals where collaborative R&D forms a part.

Chapter 4 provides a review of the leading collaborative R&D deals since 2010. Deals are listed by headline value, signed by bigpharma, most active bigpharma, signed by bigbiotech, most active bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive review of collaborative R&D financials for deals announced since 2010, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.

Chapters 6 and 7 provide a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of collaborative R&D deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive and detailed review of collaborative R&D deals signed and announced since 2010 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous table and figures that illustrate the trends and activities in collaborative R&D dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about collaborative R&D as an opportunity to participate in the commercialization of either candidate compounds in development or products already on the market.

In addition, a comprehensive appendix is provided organized by collaborative R&D company A-Z , stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about collaborative R&D partnering in the research, development and commercialization of technologies and products.


Report scope

Global Collaborative R&D Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 is intended to provide the reader with an in-depth understanding of the collaborative R&D trends and structure of deals entered into by leading life science companies worldwide.

Global Collaborative R&D Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 includes:

Trends in collaborative R&D dealmaking in the biopharma industry since 2010
Analysis of collaborative R&D deal structure
Case studies of real-life collaborative R&D deals
Comprehensive listing of collaborative R&D deals since 2010
Access to collaborative R&D contract documents
Key financial benchmarks for headline, upfront, milestone and royalty rates
The leading collaborative R&D deals by value since 2010
Most active collaborative R&D dealmakers since 2010
The leading collaborative R&D partnering resources

In Global Collaborative R&D Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 available deals and contracts are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The Global Collaborative R&D Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How do milestone align with clinical stage development phases?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Global Collaborative R&D Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 provides the reader with the following key benefits:

In-depth understanding of collaborative R&D deal trends since 2010
Analysis of the structure of collaborative R&D agreements with numerous real life case studies
Comprehensive listing of all collaborative R&D deals since 2010, together with deal terms, value and press release
Comprehensive access to actual collaborative R&D contracts entered into by the world’s life science companies
Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
Insight into the terms included in a collaborative R&D agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Global Collaborative RandD Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in collaborative RandD dealmaking

2.1. Introduction
2.2. Definition of collaborative RandD partnering
2.3. Success factors for collaborative RandD deals
2.4. When collaborative RandD can be useful
2.5. Attributes of collaborative RandD deals
2.6. Trends in collaborative RandD deals since 2010
2.7. The future of collaborative RandD deals

Chapter 3 - Overview of collaborative RandD deal structure

3.1. Introduction
3.2. Pure versus multi-component collaborative RandD deals
3.3. Pure collaborative RandD agreement structure
3.3.1. Example collaborative RandD agreements
3.3.1.a. Case study 1: Marinus Pharmaceuticals - NovaMedica - June 2013
3.3.1.b. Case study 2: Idenix Pharmaceuticals - Janssen Pharmaceuticals - January 2013
3.4. Collaborative RandD as part of a wider alliance agreement
3.4.1. Example collaborative RandD agreements and their licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics - UniQure - January 2014
3.4.1.b. Case study 4: Kyowa Hakko Kirin - Ultragenyx Pharmaceuticals - September 2013
3.4.2. Example licensing option right clauses in collaborative RandD deals
3.4.2.a. Case study 5: Forest Laboratories - Trevena - May 2013
3.4.2.b. Case study 6: Abbvie - Receptos - March 2013

Chapter 4 - Leading collaborative RandD deals

4.1. Introduction
4.2. Top collaborative RandD deals by value
4.3. Most active collaborative RandD dealmakers
4.3.1 Most active collaborative RandD dealmakers by therapy
4.3.2. Most active collaborative RandD dealmakers by stage of development
4.4. Big pharma collaborative RandD deal activity
4.5. Big biotech collaborative RandD deal activity

Chapter 5 - Collaborative RandD deal term benchmarks

5.1. Introduction
5.1.2. Collaborative RandD headline values by stage of development
5.1.2. Collaborative RandD upfront payments by stage of development
5.1.3. Collaborative RandD milestone payments by stage of development
5.1.4. Collaborative RandD royalty rates by stage of development

Chapter 6 - Big pharma collaborative RandD deals

6.1. Introduction
6.2. How to use collaborative RandD deals
6.3. Big pharma collaborative RandD agreement listings

Chapter 7 - Big biotech collaborative RandD deals
7.1. Introduction
7.2. How to use collaborative RandD deals
7.3. Big biotech collaborative RandD agreement listings

Chapter 8 - Collaborative RandD contract directory 2009-2015

8.1. Introduction
8.2. Company A-Z
8.3. By therapy area
8.4. By stage of development at signing
8.5. By technology area

Appendix
Appendix - Resources
Appendix - Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

To be found in separate PDF files accompanying this report:

Appendix 1 - Collaborative RandD dealmaking - by financial disclosure
Appendix 2 - Collaborative RandD - by companies A-Z
Appendix 3 - Collaborative RandD - by stage of development
Appendix 4 - Collaborative RandD - by therapeutic target
Appendix 5 - Collaborative RandD - by technology type

TABLE OF FIGURES

Figure 1: Definition of collaborative RandD
Figure 2: Situations where collaborative RandD can prove useful
Figure 3: Key attributes of a collaborative RandD deal
Figure 4: Trends in collaborative RandD deal announcements, 2010-2015
Figure 5: Collaborative RandD deals signed at each phase of development, 2010-2015
Figure 6: Collaborative RandD deals by therapy area, 2010-2015
Figure 7: Collaborative RandD agreements - what should a contract include?
Figure 8: Components of the collaborative RandD deal structure
Figure 9: Top collaborative RandD deals by value since 2010
Figure 10: Most active collaborative RandD dealmakers 2010-2015
Figure 11: Most active collaborative RandD dealmakers 2010-2015 by therapy
Figure 12: Most active collaborative RandD dealmakers 2010-2015 - by stage of development
Figure 13: Big pharma - top 50 - collaborative RandD deals 2010 to 2015
Figure 14: Big pharma collaborative RandD deal frequency - 2010 to 2015
Figure 15: Bigbiotech - top 50 - collaborative RandD deals 2010 to 2015
Figure 16: Bigbiotech collaborative RandD deal frequency - 2010 to 2015
Figure 17: Collaborative RandD deal headline value distribution, US$million - discovery stage
Figure 18: Collaborative RandD deal headline value distribution, US$million - preclinical stage
Figure 19: Collaborative RandD deal headline value distribution, US$million - phase I stage
Figure 20: Collaborative RandD deal headline value distribution, US$million - phase II stage
Figure 21: Collaborative RandD deal headline value distribution, US$million - phase III stage
Figure 22: Collaborative RandD deal headline value distribution, US$million - regulatory stage
Figure 23: Collaborative RandD deal headline value distribution, US$million - marketed stage
Figure 24: Summary median collaborative RandD headline value by stage of development, 2010-2015
Figure 25: Collaborative RandD deal upfront payment distribution, US$million - discovery stage
Figure 26: Collaborative RandD deal upfront payment distribution, US$million - preclinical stage
Figure 27: Collaborative RandD deal upfront payment distribution, US$million - phase I stage
Figure 28: Collaborative RandD deal upfront payment distribution, US$million - phase II stage
Figure 29: Collaborative RandD deal upfront payment distribution, US$million - phase III stage
Figure 30: Collaborative RandD deal upfront payment distribution, US$million - regulatory stage
Figure 31: Collaborative RandD deal upfront payment distribution, US$million - marketed stage
Figure 32: Summary median collaborative RandD upfront payments by stage of development, 2010-2015
Figure 33: Collaborative RandD deal milestone distribution, US$million - discovery stage
Figure 34: Collaborative RandD deal milestone distribution, US$million - preclinical stage
Figure 35: Collaborative RandD deal milestone distribution, US$million - phase I stage
Figure 36: Collaborative RandD deal milestone distribution, US$million - phase II stage
Figure 37: Collaborative RandD deal milestone distribution, US$million - phase III stage
Figure 38: Collaborative RandD deal milestone distribution, US$million - regulatory stage
Figure 39: Collaborative RandD deal milestone distribution, US$million - marketed stage
Figure 40: Collaborative RandD deals with royalty rates, %
Figure 41: Summary median collaborative RandD royalty rate by stage of development, 2010-2015
Figure 42: Online partnering resources
Figure 43: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2016

Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2016

  • $ 2995
  • Industry report
  • September 2016
  • by Currentpartnering

The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016 report provides comprehensive understanding and unprecedented access to the collaborative R&D deals ...

Top 20 Companies Developing Autonomous Vehicles (AV) Technologies 2016

Top 20 Companies Developing Autonomous Vehicles (AV) Technologies 2016

  • $ 2257
  • Industry report
  • August 2016
  • by Visiongain

Report Details This revolutionary report from market intelligence provider visiongain offers comprehensive insight into the top 20 companies developing autonomous vehicles in 2016. Benefits of This Report ...

Scientific Research and Development (R&D) in Physics, Engineering, Telecommunications and Computers Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts: NAIC 541712

Scientific Research and Development (R&D) in Physics, Engineering, Telecommunications and Computers Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts: NAIC 541712

  • $ 1995
  • Industry report
  • November 2016
  • by Plunkett Research

Scientific Research and Development (R&D) in Physics, Engineering, Telecommunications and Computers Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2023, NAIC ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.